CD34 and acute lymphoblastic leukemia: The anti-CD122-conditioned NOD/SCID xenograft mouse assay with IBMI and the finding that LPCs were enriched in the CD34+CD38−CD58− fraction in Ph+ALL patients provided us with a useful LPCs target and xenograft model for examining the anti-LPCs efficacy of drug treatment in Ph+ALL [10].